Reproductive Health

Menstrual cycle length may be an accurate predictor of ovarian aging due to its association with ovarian reserve test values and fecundability rates, according to a systemic review published in Human Reproduction Update.

Women with early ovarian aging are more likely to incur age-related diseases than those with normal ovarian aging, according to study results published in Human Reproduction.

A report from the Endocrine Society and International Pollutants Elimination Network identifies more than 140 endocrine-disrupting chemicals, or EDCs, and their negative effects on human health.

President-elect Joseph R. Biden Jr. announced key members of his health team today — individuals he called “trusted, accomplished” and “ready from day one” to bring the COVID-19 pandemic under control.

Women in states with the least restrictive reproductive rights policies have a lower risk for low birth weight compared with women who live in the most restrictive states, according to findings from a retrospective, cross-sectional study.

Implementing a program-level incentive metric may increase use of effective contraceptives among Medicaid beneficiaries, according to results from a study published in JAMA Network Open.

Women aged 18 to 45 years with rheumatic diseases want rheumatologists to play an active role in their sexual and reproductive health, according to findings from a series of interviews published in Arthritis Care & Research.

The HHS announced that it has finalized a rule that allows the government to interpret sex discrimination based on the definition of the word “sex” as male or female and biology — a move the agency also said “protects and enforces the civil rights of all.”

The American College of Rheumatology has issued a strong recommendation that women with rheumatic disease who do not have lupus or antiphospholipid syndrome use effective contraceptives, along with 130 other recommendations in its first clinical practice guideline for reproductive health.

I did my internal medicine residency at Yale New Haven Hospital in the years immediately before the advent of protease inhibitors would change the face of ART. In addition to caring for many young gay men with AIDS, I saw the side of the epidemic that even today remains relatively hidden in the United States, and is operative throughout much of sub-Saharan Africa: young women — often black — who presented late in the disease, having been infected by boyfriends or husbands. I was on call when one of my favorite patients, Shirley B., was admitted to die, and the team paged me to let me know so I could see her. I’ll never forget their kindness in doing that and my visit to her room. These experiences solidified not only my interest in ID but in advancing women’s reproductive health and autonomy related to ID and HIV prevention. Vaginal health? Female-controlled prevention methods? These were not sexy concepts that attracted big names during my subsequent training and early research career. Luckily, through persistence and commitment and probably some measure of stubborn cluelessness, I connected with some brave visionary mentors who believed there was a future in this arena and who themselves had battled for sexual and reproductive health — women, LGBT people, others not always at the proverbial table when funding or policy priorities are set. The rest is my personal history, and I know that only in ID would I have been able to accomplish any of it.